About NEDP
NEDP is a Healthcare company based in Branford (United States) founded in 2012, and was acquired by Genesis Biotechnology Group in November 2019. Chemistry-focused drug development and structure-based design services are offered. NEDP offers products and services including Drug Discovery Services, Process Chemistry, Custom Synthesis, and Analytical Services. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Medicinal Chemistry. Its legal entity is New England Discovery Partners LLC.
Company details
New England Discovery Partners is an integrated chemistry focussed CRO that specialises in synthetic and medicinal chemistry and structure-based drug design. Their synthetic chemistry services cater to several types of products including peptides, carbohydrates, heterocycles, phospholipids and several others. Their med chem services include hit conformation and expansion, lead optimisation and X-ray crystallography of small molecule inhibitors bound to protein targets. They offer structure based drug design services through their capabilities such as protein production and purification, X-ray crystallography and molecular modelling. The company also offers NMR, Optical Rotation and infrared and UV-visible spectroscopy based analytical services on a fee-for-service (FFS) basis.
- Headquarters Branford, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nedp.com
- Social LinkedIn
- Acquired by Genesis Biotechnology Group (Nov 2019)
- Legal Name New England Discovery Partners Llc
- Latest Funding Round$593.84K (USD), Grant
Aug 2017
- InvestorsHHS
& 1 more
- Acquired byGenesis Biotechnology Group
(Nov 2019)
Products & Services of NEDP
NEDP offers a comprehensive portfolio of products and services, including Drug Discovery Services, Process Chemistry, Custom Synthesis, and Analytical Services.
Services for identifying and developing new clinical compounds.
Expert services in chemical process development and optimization.
Tailored synthesis of organic compounds for various applications.
Testing and analysis for drug discovery and chemical research.
Funding Insights of NEDP
- Total Rounds 2
- Last Round Grant — $593,835
- First Round $210,540
(Jun 2015)
- Investors Count 1
All 2 funding rounds of NEDP with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in NEDP
NEDP has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Genesis Biotechnology Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
A consortium of companies focused on improving patient care. | genesisbiotechgroup.com | Hamilton, United States |
Investor details for NEDP
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NEDP
4 dated milestones of NEDP across 7 years, from founding to its latest funding, stage changes and deals.
- Founded NEDP is founded.
- Funding First funding round of $211K.
- Funding Latest funding round, Grant, of $594K.
- Exit Acquired by Genesis Biotechnology Group.
Web traffic of NEDP
The website of NEDP (nedp.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 18.4% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as NEDP (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nedp
Complete news archive for NEDP
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NEDP
NEDP was founded in 2012 and raised its 1st funding round 3 years after it was founded.
NEDP is headquartered in Branford, United States. It is registered at Branford, Connecticut, United States.
New England Discovery Partners is an integrated chemistry focussed CRO that specialises in synthetic and medicinal chemistry and structure-based drug design. Their synthetic chemistry services cater to several types of products including peptides, carbohydrates, heterocycles, phospholipids and several others. Their med chem services include hit conformation and expansion, lead optimisation and X-ray crystallography of small molecule inhibitors bound to protein targets. They offer structure based drug design services through their capabilities such as protein production and purification, X-ray crystallography and molecular modelling. The company also offers NMR, Optical Rotation and infrared and UV-visible spectroscopy based analytical services on a fee-for-service (FFS) basis.
NEDP offers Drug Discovery Services, Process Chemistry, Custom Synthesis, and Analytical Services.
NEDP has 2 investors. Key investors include HHS, and Genesis Biotechnology Group.
NEDP operates through New England Discovery Partners Llc.
Yes. NEDP was acquired by Genesis Biotechnology Group in November 2019.